Skip to main content

AS/Spondyloarthritis

      RT @uptoTate: Dr. M. Dubreuil shares a beautiful slide describing the asynchrony between the goal and the reality in the
      4 years 5 months ago
      Dr. M. Dubreuil shares a beautiful slide describing the asynchrony between the goal and the reality in the classification of axSpA. Do you think it’s time to change our nomenclature and classification criteria? #ACR20 @RheumNow https://t.co/YJcvLKnyFy
      RT @uptoTate: Dr. J. Kay reviews ICD11 classification codes for medical claims for diagnosing SpA which reviews ASAS cri
      4 years 5 months ago
      Dr. J. Kay reviews ICD11 classification codes for medical claims for diagnosing SpA which reviews ASAS criteria. This likely won’t be adopted in the US for several years. #ACR20 ⁦@RheumNow⁩ https://t.co/oDhs1EHSTP
      RT @uptoTate: Do you know Walter Bauer, MD #ACR20? Well, I didn't either! Dr. M. Weinblatt taught me that Dr. Bauer was
      4 years 5 months ago
      Do you know Walter Bauer, MD #ACR20? Well, I didn't either! Dr. M. Weinblatt taught me that Dr. Bauer was an important US rheumatologist who did NOT believe AS was a separate disease entity from RA! It wasn't until his death that the college recognized both separately! @RheumNow
      RT @doctorRBC: Gender differences in Axial Spondyloarthritis patientsPooled data from 3 Ixekizumab studiesWomen:1⃣o
      4 years 5 months ago

      Gender differences in Axial Spondyloarthritis patients Pooled data from 3 Ixekizumab studies Women: 1⃣older at disease onset (30 vs. 26) 2⃣Longer symptom duration (17.8 yrs vs. 16.7 yrs) 3⃣More peripheral joint pain and lower HLA-B27 @RheumNow #ACR20 Abs#0876 https://t.co/qGHXApi0Ko

      RT @Janetbirdope: Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some min
      4 years 5 months ago

      Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ

      RT @uptoTate: MEASURE2 and COAST-W data stratified by TNFi inadequate responders may suggest different axSpA subset (dom
      4 years 5 months ago
      MEASURE2 and COAST-W data stratified by TNFi inadequate responders may suggest different axSpA subset (domain?) response to TNFi vs IL17i. Dr. J. Ermann #ACR20 @RheumNow #ACRbest https://t.co/0ZcEIvkuMj
      RT @synovialjoints: Which Axial SpA outcome score do you use in clinic as a target to achieve? @RheumNow #ACR20
      4 years 5 months ago
      Which Axial SpA outcome score do you use in clinic as a target to achieve? @RheumNow #ACR20
      ×